A 48-Week, Randomized, Open-Label Phase 3B Study Comparing the Antiviral Efficacy and Safety of ATV/RTV 3TC With ATV/RTV Plus TDF/FTC In HIV-1-Infected, Treatment-Naive Subjects, Followed By a 48-Week Period on ATV/RTV Plus 3TC

Trial Profile

A 48-Week, Randomized, Open-Label Phase 3B Study Comparing the Antiviral Efficacy and Safety of ATV/RTV 3TC With ATV/RTV Plus TDF/FTC In HIV-1-Infected, Treatment-Naive Subjects, Followed By a 48-Week Period on ATV/RTV Plus 3TC

Discontinued
Phase of Trial: Phase III

Latest Information Update: 20 May 2014

At a glance

  • Drugs Atazanavir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate; Lamivudine; Ritonavir
  • Indications HIV-1 infections
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Most Recent Events

    • 10 Dec 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 01 Dec 2012 New source identified and integrated: European Clinical Trials Database EudraCT2011-006187-47.
    • 20 Oct 2012 Status changed from not yet recruiting to recruiting as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top